title: [Evaluation of the results of treating progressive multiple sclerosis with cyclophosphamide].
abstract: Cyclophosphamide (4000 mg intravenously, in daily doses of 400 mg) in combination with moderate dose of prednisone (1075 mg during 30 days) was given to 39 patients with the chronically progressing form of multiple sclerosis. The results of this treatment were evaluated immediately after the treatment and one and two years later, using a numerical scale of neurological examination in the scales of motor efficiency A. I. (ambulation index) and the DDS (disability status scale of Kurtzke). In the first year after this treatment stabilization of the disease (60% of cases) or even clinical improvement (10-20%) were noted. However, in the second year after the treatment an evident progression of symptoms occurred in 50-60% of cases. In view of moderately positive results of this treatment it is necessary to carry out observations extended over many years, to repeat cyclophosphamide cycles, and to compare the results with those after other immunosuppressants.
authors.affiliation: I Katedry i Kliniki Neurologii Sl. AM w Katowicach.
authors.forename: A
authors.initials: A
authors.lastname: Wajgt
authors.forename: K
authors.initials: K
authors.lastname: Szyrocka-Szwed
authors.forename: B
authors.initials: B
authors.lastname: Gadomska
authors.forename: L
authors.initials: L
authors.lastname: Szczechowski
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage*; D012074:Remission Induction; D013997:Time Factors
chemical_list: D003520:Cyclophosphamide; D011241:Prednisone
vernacular_title: Ocena wyników leczenia cyklofosfamidem przypadków stwardnienia rozsianego o przebiegu postepujacym.